B ALL is due to –
B ALL is a type of leukemia affecting B-lymphocytes. The question is asking what causes it. The core concept would involve the genetic mutations or chromosomal abnormalities that lead to the malignant transformation of B-cell precursors. Common causes include chromosomal translocations, such as the Philadelphia chromosome (t(9;22)) which leads to the BCR-ABL1 fusion gene. Other translocations like t(1;19) for E2A-PBX1 and t(12;21) for TEL-AML1 are also involved. These mutations disrupt normal cell cycle regulation and apoptosis.
Now, the correct answer is likely one of these translocations. For instance, the Philadelphia chromosome is a well-known cause. But without the options, I need to infer based on common exam questions. Let's suppose the options are different translocations or other causes. The correct answer would be the one that's a known translocation in B ALL.
The wrong options might include translocations associated with other leukemias, like the t(15;17) in APL (Acute Promyelocytic Leukemia), or maybe something like t(8;14) in Burkitt's lymphoma. Or perhaps a viral cause like EBV, which is more associated with other lymphomas but not typically B ALL.
The clinical pearl here is that the most common translocations in B ALL include t(12;21), t(1;19), t(5;14), and t(9;22). The Philadelphia chromosome (t(9;22)) is particularly significant because it leads to the BCR-ABL1 fusion protein, which is a target for tyrosine kinase inhibitors like imatinib.
So, putting it all together, the explanation should highlight the specific chromosomal translocations responsible for B ALL, why the correct answer is right (e.g., t(9;22)), and why others are incorrect (like t(15;17) for APL). The clinical pearl reinforces the key translocations and their associated treatments.
**Core Concept**
B-cell Acute Lymphoblastic Leukemia (B ALL) arises from genetic abnormalities in B-cell precursors. Key mutations include chromosomal translocations like t(9;22) (Philadelphia chromosome), t(1;19), and t(12;21), which disrupt oncogenes or tumor suppressors, leading to uncontrolled proliferation. These are central to pathogenesis in pediatric and adult cases.
**Why the Correct Answer is Right**
The correct answer identifies **t(9;22)** (Philadelphia chromosome), which fuses *BCR* and *ABL1* genes, creating the **BCR-ABL1 tyrosine kinase fusion protein**. This constitutively active kinase drives cell cycle progression and apoptosis resistance in B ALL. It is a hallmark of Philadelphia chromosome-positive ALL, a high-risk subtype responsive to tyrosine kinase inhibitors like imatinib.
**Why Each Wrong Option is Incorrect